Kazia Shares Drop 17% After Announcing ADS Offering With Warrants
KZIA has more than doubled off its 52-week low of $4.86 on elevated volume (5.1× avg).
Summary
Kazia Therapeutics disclosed a tranched registered public offering of ADSs and warrants, sending shares down 17% to $14.10 in premarket trading. The offering follows Thursday's 16% surge after the company reported 100% clinical benefit in six evaluable Stage IV TNBC patients treated with paxalisib. The deal includes pre-funded warrants and Series A/B warrants exercisable at more than double the IPO price, with expirations tied to paxalisib trial readouts expected in late 2027 and early 2028. Kazia priced the offering at $15.50 per ADS, with 2,276,800 ADSs and pre-funded warrants for 303,200 ADSs, raising about $40 million before underwriting discounts. Series A warrants have a $17.825 exercise price and Series B warrants $19.375. Proceeds will fund paxalisib development and working capital. Leerink Partners and Guggenheim Securities are joint bookrunners. The dilution and warrant overhang are pressuring the stock after a strong run.
Updated with an SEC 424B5 filing · What changed
Updates
· SEC 424B5 — Kazia priced the offering at $15.50 per ADS, with 2,276,800 ADSs and pre-funded warrants for 303,200 ADSs, raising about $40 million before underwriting discounts. Series A warrants have a $17.825 exercise price and Series B warrants $19.375.
At the time of this announcement, KZIA was trading at $13.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $193.1M. The 52-week trading range was $4.86 to $17.40. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.